Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Tirzepatide · maintenance

Tirzepatide maintenance: continue, reduce, or stop?

What SURMOUNT-4 shows about maintaining tirzepatide weight loss, and reduced vs microdose maintenance.

Maintenance is where tirzepatide decisions get hard: the SURMOUNT-4 withdrawal trial showed that stopping the approved product leads to substantial weight regain, while continuing preserves the loss. That makes tirzepatide a long-term commitment for most people. 'Reduced maintenance' and 'microdose maintenance' are different ideas — one is a clinician lowering an established dose, the other is a marketing term — and only the former has any trial signal.

What the withdrawal trials show

In SURMOUNT-4, people who continued approved tirzepatide maintained their weight loss, while those switched to placebo regained a large share of it. The related maintenance-design evidence points the same way: the physiology that drives weight loss also drives regain when the drug is removed. This is not a failure of willpower; it is how the medication works.

Tirzepatide's maintenance evidence is richer on one point semaglutide lacks: alongside SURMOUNT-4's withdrawal finding of regain after stopping, the SURMOUNT-MAINTAIN design specifically studied a reduced 5 mg maintenance dose against the maximum tolerated dose. That makes reduced-dose maintenance a somewhat more studied concept for tirzepatide than for semaglutide — though it is still a clinical decision, and a commercial 'microdose maintenance' remains a different, unproven idea.

The reduced-maintenance question

Some clinicians lower the dose once a patient reaches a stable weight, watching for regain. Evidence for a specific reduced-maintenance dose is limited though a reduced-dose maintenance design has been studied for this molecule, so it is an individualized clinical decision, not a published schedule. This site does not publish a maintenance or tapering schedule.

No schedule here. We do not publish a maintenance or off-ramping schedule for tirzepatide. Adjusting or stopping is a decision to make with your prescriber.

What the evidence shows

  • Continuing approved tirzepatide maintains weight loss; stopping is associated with regain (SURMOUNT-4).

What the evidence does not show

  • That a specific 'microdose maintenance' preserves results — unproven.
  • That any universal reduced-dose schedule is safe or effective.

Frequently asked questions

Do I have to take tirzepatide forever?

For many people it is a long-term treatment: SURMOUNT-4 showed regain after stopping. Any change should be planned with a prescriber.

Does a microdose maintain weight loss?

Unproven. Withdrawal trials show regain after stopping; a sub-therapeutic maintenance dose has no comparable evidence.

See managing side effects and the off-ramping evidence.

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.